De Ciuceis Carolina, Rossini Claudia, Tincani Angela, Airò Paolo, Scarsi Mirco, Agabiti-Rosei Claudia, Ruggeri Giuseppina, Caimi Luigi, Ricotta Doris, Agabiti-Rosei Enrico, Rizzoni Damiano
a Internal Medicine, Department of Clinical and Experimental Sciences , University of Brescia , Brescia , Italy.
b Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences , University of Brescia , Brescia , Italy.
Blood Press. 2016 Dec;25(6):337-343. doi: 10.1080/08037051.2016.1184495. Epub 2016 May 19.
It has been demonstrated that circulating endothelial progenitor cells (EPCs) number reflects the endogenous vascular repair ability, with the EPCs pool declining in presence of cardiovascular risk factors. Several drugs, including dihydropyridine calcium channel blockers, have been reported to elicit antioxidant and anti-inflammatory properties, as well as to improve vascular remodeling and dysfunction. However, no data are available about the effects of lercanidipine on EPCs. The aim of the present study was therefore to investigate the effects of short-term treatment with lercanidipine on circulating EPCs, as well as on indices of inflammation and oxidative stress.
Twenty essential hypertensive patients were included in the study and treated for 4 weeks with lercanidipine 20 mg per day orally. Investigations were performed in basal condition, after appropriate wash out of previous treatments, and after 4 weeks of lercanidipine treatment. Inflammatory and oxidative stress markers were assessed by ELISA technique. Lin-/7AAD-/CD34+/CD133+/VEGFR-2 + and Lin-/7AAD-/CD34+/VEGFR-2 + cells were identified by flow cytometry and considered as EPCs. EPCs cells were expressed as number of cells per million Lin-mononuclear cells.
Circulating EPCs were significantly increased after lercanidipine treatment (CD34+/CD133+/VEGFR-2 + cells: 78.3 ± 64.5 vs 46.6 ± 32.8; CD34+/VEGFR-2+: 87996 ± 165116 vs 1026 ± 1559, respectively, p < 0.05). A modest reduction in circulating indices of inflammation was also observed.
In conclusion, lercanidipine is able to increase the number of circulating EPCs, possibly through a reduction of low-grade inflammation.
已有研究表明，循环内皮祖细胞（EPCs）数量反映内源性血管修复能力，在存在心血管危险因素时EPCs池会减少。据报道，包括二氢吡啶类钙通道阻滞剂在内的几种药物具有抗氧化和抗炎特性，还能改善血管重塑和功能障碍。然而，关于乐卡地平对EPCs的影响尚无数据。因此，本研究的目的是探讨乐卡地平短期治疗对循环EPCs以及炎症和氧化应激指标的影响。
本研究纳入了20例原发性高血压患者，每天口服20mg乐卡地平治疗4周。在基础状态下、适当洗脱先前治疗后以及乐卡地平治疗4周后进行检查。通过ELISA技术评估炎症和氧化应激标志物。通过流式细胞术鉴定Lin-/7AAD-/CD34+/CD133+/VEGFR-2+和Lin-/7AAD-/CD34+/VEGFR-2+细胞，并将其视为EPCs。EPCs细胞以每百万Lin-单核细胞中的细胞数表示。
乐卡地平治疗后循环EPCs显著增加（CD34+/CD133+/VEGFR-2+细胞：分别为78.3±64.5对46.6±32.8；CD34+/VEGFR-2+：87996±165116对1026±1559，p<0.05）。还观察到循环炎症指标有适度降低。
总之，乐卡地平能够增加循环EPCs的数量，可能是通过减轻低度炎症实现的。
